Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

PURPOSE: Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. METHODS: The study presented...

Full description

Saved in:
Bibliographic Details
Main Authors: Wehler, Thomas C., Graf, Claudine, Möhler, Markus, Herzog, Jutta, Berger, Martin R., Gockel, Ines, Lang, Hauke, Theobald, Matthias, Galle, Peter R., Schimanski, Carl C.
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2013
Subjects:
Original Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771414/
https://ncbi.nlm.nih.gov/pubmed/23918349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-013-1483-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items